P2, N=26, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

1 day ago

Trial completion date • Trial primary completion date

TP53 (Tumor protein P53) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)

TP53 mutation • MSI-H/dMMR

Keytruda (pembrolizumab) • Lynparza (olaparib)

Targeting of MARK2, but not other MARKs, suppresses TNBC progression by inhibition of the mutant p53-driven signaling pathway. (PubMed, Chin J Nat Med)

Consistent with this, MARK2-ΔUBA or MARK2-ΔSpacer mutant proteins fail to bind mutp53 or sustain its signaling, thereby acting as dominant-negative inhibitors that suppress TNBC progression. Collectively, our findings indicate that suppressing MARK2 expression, rather than inhibiting its kinase activity, may represent an effective therapeutic strategy for TNBC with mutTP53.

1 day ago

Journal

MARK2 (Microtubule Affinity Regulating Kinase 2) • MARK4 (Microtubule Affinity Regulating Kinase 4)

TP53 mutation • TP53 wild-type

p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells. (PubMed, Biochem Biophys Res Commun)

p53-R248W confers selective doxorubicin resistance to multiple cancer cells through TOP2A suppression and CYP1A1/A2 overexpression. These findings highlight the mutation specific mechanism of doxorubicin resistance that might result in poor response and needs to be considered during treatment plan.

1 day ago

Journal • PARP Biomarker

TOP2A (DNA topoisomerase 2-alpha) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1)

TP53 mutation

cisplatin • doxorubicin hydrochloride

Firmonertinib for Adjuvant Therapy in Completely Resected Stage IA EGFR-Mutated NSCLC (ChiCTR2600121611)

P4, N=535, Recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital

2 days ago

New P4 trial • Real-world evidence

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • NRG1 (Neuregulin 1) • BRCA (Breast cancer early onset)

TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • ALK positive • RET fusion • ALK fusion • FGFR mutation • RET mutation • ROS1 fusion • MET mutation • RB1 mutation • NRG1 fusion • KRAS G12 • BRCA mutation

Ivesa (firmonertinib)

Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients (clinicaltrials.gov)

P=N/A, N=344, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Nov 2026 | Trial primary completion date: Apr 2026 --> Nov 2026

2 days ago

Trial completion date • Trial primary completion date

TP53 mutation

Integrated Multiomic Profiling Enhances Risk Stratification and Prognostication in Canine Osteosarcoma. (PubMed, Clin Cancer Res)

This work highlight the complexity of the disease and provide new insight into the utility of prognostic biomarkers and potential druggable targets for future study.

3 days ago

Journal

TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PTEN (Phosphatase and tensin homolog)

TP53 mutation • PTEN mutation

Integration of circulating tumor DNA profiling in the risk stratification of classical Hodgkin lymphoma in children, adolescents, and young adults. (PubMed, Hemasphere)

XPO1 and IGLL5 mutations were associated with a higher risk of relapse. The presence of detectable ctDNA after two cycles of chemotherapy (10%) was a strong and independent prognostic marker of relapse.

3 days ago

Journal • IO biomarker • Circulating tumor DNA

TP53 (Tumor protein P53) • XPO1 (Exportin 1) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5)

TP53 mutation

Prognostic Stratification and Subtyping of Glioblastoma Using Transient Receptor Potential Channels. (PubMed, Hum Mutat)

High TRPRS was associated with diminished cytotoxic T-cell infiltration and predicted resistance to multiple therapeutics-including cisplatin, carmustine, gefitinib, buparlisib, and afatinib. Functional assays demonstrated that IFNGR2 knockdown suppressed glioma cell proliferation and attenuated NF-κB signaling, underscoring its role as a key driver within the TRP network. TRPRS provides a robust, biologically grounded tool for simultaneous prognostication and therapy guidance in GBM, highlighting TRP signaling as a therapeutic vulnerability.

3 days ago

Journal • IO biomarker

TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2)

TP53 mutation

cisplatin • Gilotrif (afatinib) • gefitinib • buparlisib (AN2025) • carmustine

Multiomics Analysis Identifies Chromosomal Instability-Associated Immune-Related Signatures in Hepatocellular Carcinoma by Integrating Weighted Gene Coexpression Network Analysis (WGCNA) and Machine Learning. (PubMed, Hum Mutat)

High-risk patients exhibited poorer survival, increased immune cell (particularly T cell) infiltration, higher sensitivity to chemotherapeutics like 5-fluorouracil and paclitaxel, and a higher TP53 mutation rate. Additionally, SSRP1 and SETDB1 were verified to promote the proliferation and invasion of HCC cells. This integrated model, combining genomic and immunological features, is a reliable prognostic tool for HCC patient stratification and personalized chemotherapy, promising for clinical translation and precision medicine in HCC.

3 days ago

Journal

TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ARID2 (AT-Rich Interaction Domain 2) • SETDB1 (SET Domain Bifurcated Histone Lysine Methyltransferase 1) • SSRP1 (Structure Specific Recognition Protein 1)

TP53 mutation

paclitaxel • 5-fluorouracil

N-WASP is downregulated in patients with acute myeloid leukemia (AML) and is associated with poor prognosis. (PubMed, Sci Rep)

Collectively, these results demonstrate that N-WASP is suppressed in AML and is closely associated with disease risk and clinical outcome. N-WASP may serve as a novel prognostic biomarker and potential therapeutic target warranting further investigation.

3 days ago

Journal

BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1)

TP53 mutation

Next-Generation Sequencing-Based Analysis of the Genetic Mutation Spectrum in Colorectal Cancer: A Large Single‑Center Study From Southeast China With Cross‑Population Comparison. (PubMed, Mol Carcinog)

This study demonstrates significant associations between specific gene mutations and distinct clinicopathological characteristics. The findings underscore the importance of integrating molecular profiling with conventional clinicopathological parameters for precise stratification.

3 days ago

Journal • Next-generation sequencing • MSi-H Biomarker

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability)

TP53 mutation • KRAS mutation • MSI-H/dMMR • PIK3CA mutation